<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7049676/table_4" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 4</label>
  <p>Considerations for Antiviral Selection for HBV Treatment</p>
 </caption>
 <col style="border-right:solid 1px #000000" span="1"/>
 <col style="border-right:solid 1px #000000" span="1"/>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-.">col0</th>
  </tr>
 </thead>
 <tbody>
  <tr style="border-bottom:solid 1px #000000">
   <td align="left" colspan="2" rowspan="1">AASLD</td>
  </tr>
  <tr>
   <td align="left" style="padding-left:10%" rowspan="3" colspan="1">Guidance statements</td>
   <td align="left" rowspan="1" colspan="1">No preference between ETV or TDF regarding potential long‐term risks of renal and bone complications</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">TAF is associated with lower rates of bone and renal abnormalities than TDF</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">In cases of suspected TDF‐associated renal dysfunction and/or bone disease, TDF should be discontinued and substituted with TAF or ETV, with consideration for any previously known drug resistance</td>
  </tr>
  <tr>
   <td align="left" colspan="2" rowspan="1">EASL</td>
  </tr>
  <tr>
   <td align="left" style="padding-left:10%" rowspan="11" colspan="1">Indications for selection of ETV or TAF over TDF</td>
   <td align="left" rowspan="1" colspan="1">
    <b>Age</b>
   </td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">&gt; 60 years</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">
    <b>Bone disease</b>
   </td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Chronic use of medications that worsen bone density (including steroids)</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">History of fragility fractures</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Osteoporosis</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">
    <b>Renal dysfunction</b>
   </td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">eGFR &lt;60 mL/min/1.73 m 
    <sup>2</sup>
   </td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Albuminuria &gt;30 mg/24 hours or urinalysis with moderate qualitative proteinuria</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">Hypophosphatemia (&lt;2.5 mg/dL)</td>
  </tr>
  <tr>
   <td align="left" rowspan="1" colspan="1">On hemodialysis</td>
  </tr>
  <tr>
   <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Recommendation statements</td>
   <td align="left" rowspan="1" colspan="1">Patients on TDF at risk of development and/or with underlying renal or bone disease should be considered for a switch to ETV or TAF, depending on previous treatments</td>
  </tr>
 </tbody>
 <tfoot>
  <p class="fn" charset="fn" id="hep41480-note-0013">
   <p>Abbreviations: eGFR, estimated glomerular filtration rate; ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.</p>
  </p>
 </tfoot>
</table>
